AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2640-1045/116
1 Endocrinology Sector, Central Laboratory of the Dr. Oscar Alende Interzonal General Acute Hospital, Mar del Plata, Bs As, Argentina.
2 Central Laboratory, Clinic and Maternity Colon, Mar del Plata, Bs As, Argentina.
3 Endocrinology Service of the Hospital General de Agudos Dr. Teodoro Álvarez, Bs As, Argentina.
*Corresponding Author: Belloni J, Endocrinology Sector, Central Laboratory of the Dr. Oscar Alende Interzonal General Acute Hospital, Clinic and Maternity Colon, Mar del Plata, Bs As, Argentina.
Citation: Belloni J and Tapper X. (2022). Glp-1 Analogs for the Treatment of Obesity and Diabetes. Endocrinology and Disorders, 6(2); DOI:10.31579/2640-1045/116
Copyright: © 2022, Belloni J. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 16 January 2022 | Accepted: 26 March 2022 | Published: 25 April 2022
Keywords: diabetes; obesity; incretins; incretin effect; GLP-1 analogs
Currently the prevalence of obesity and diabetes is increasing throughout the world. The unsatisfactory long-term results observed in the treatment of both are due to their complex pathophysiologies and the difficulties related to maintaining lifestyle changes. From the knowledge of the incretin effect and its alteration in patients with type 2 diabetes mellitus, GLP-1 receptor agonists arise, molecules with high structural homology with native GLP-1. Scientific evidence supports its use for the long-term treatment of diabetes, especially in the presence of associated cardiovascular and/or renal failure. In 2009, the use of liraglutide for patients with diabetes was approved in Europe, and in 2014 it was signed for the first time in the United States to treat obesity, since it was observed that the use of these drugs causes significant weight loss.
Diabetes is a chronic disease in continuous growth worldwide. Type 2 diabetes mellitus represents 90% of cases and its frequency is similar to that of obesity. The latter currently affects more than 600 million people worldwide and is associated with more than 45 comorbidities, in addition to the atherogenic affectation that makes up the metabolic syndrome. Obesity is one of the main causes of insulin resistance and can progress to type 2 diabetes [1,2]. Lifestyle modifications continue to be the first-line treatment for obesity, although they have been shown to only confer modest benefits [3].
Incretins are hormones secreted by enteroendocrine cells upon nutrient intake. They stimulate insulin secretion by pancreatic β cells in a glucose-dependent manner. In the search for pharmacological therapies, incretin analogs have emerged with proven benefits in improving blood glucose, weight loss, and cardiovascular outcomes [4.5].
This monograph aims to present the usefulness of GLP-1 analogs for the treatment of patients with diabetes and obesity based on the most relevant clinical trials published to date.
Intestinal hormones act on various tissues involved in the control of intestinal function, insulin secretion, nutrient assimilation and food intake [6]. In 1903 Moore et al, described the presence of “a substance of a hormonal nature or secretin, produced by the duodenal mucosal membrane that would be absent in diabetic patients”. GIP (glucose-dependent insulinotropic polypeptide), the first incretin, was found in 1973, and GLP-1 (glucagon-like peptide 1) was discovered in 1987. In 1979, Creutzfeldt defined the criteria for classifying a substance as incretin: gastrointestinal factor, involved in nutrient metabolism that should stimulate insulin secretion in a glucose-dependent manner at physiological levels. To date, GIP and GLP-1 are the only ones that meet these criteria [4].
Physiology of incretins
GIP is produced by K cells in the mucosa of the duodenum and upper jejunum. It is synthesized as a precursor propeptide (pro-GIP), which is then cleaved into GIP by post-translational processing. It not only accelerates insulin secretion under hyperglycemic conditions, but also stimulates glucagon secretion under hypoglycemic conditions. The binding of GIP to its receptor called GIP-R, with seven transmembrane domains coupled to guanine nucleotide binding protein, leads to the activation of adenylate cyclase and an increase in cyclic adenosine monophosphate (cAMP), with the consequent activation of protein kinase type A (PKA). GIP-R is expressed in pancreas, intestine, heart, adipose tissue, and brain [6].
GLP-1 was identified as part of the gene sequence encoding pro-glucagon, which is expressed on L cells in the small and large intestine. Processing of pro-glucagon in intestinal L cells results in the formation of glucagon, GLP-1, and GLP-2 (an intestinal growth factor). The GLP-1 molecule is converted into an active molecule by the effect of proconvertase-1. The GLP-1 receptor is expressed in the intestine, pancreas, brainstem, hypothalamus, and vagal afferent nerves. It is also a G protein-coupled receptor that triggers the same intracellular signaling pathway as the GIP-R. The actions of GLP-1 include activation of the ileal brake, delayed gastric emptying, increased glucose-dependent insulin release, decreased glucagon secretion, and increased pancreatic β-cell growth. GLP-1 decreases food intake, possibly through direct vagal and central pathways, mediated specifically by GLP-1 receptors [5,6]. The secretion of GLP-1 occurs almost in parallel with the secretion of GIP, this indicates that there would be signals sent by the nervous system autonomic gut that trigger the release of GLP-1. It should be noted that incretins also have some other additional biological effects [7]. (Figure 1)
Endogenous GLP-1 and GIP have a short plasma half-life: 1 to 7 minutes and are rapidly metabolized and inactivated by the enzyme DPP-4 (Dipeptidyl peptidase – 4). This ubiquitous enzyme is present in the circulation and is expressed on the surface of most cell types [8].
Oral glucose leads to greater stimulation of insulin secretion than intravenous infusion even when the same plasma glucose concentration profiles ("isoglycemia") are achieved. This phenomenon is called the incretin effect and is attributed to the release of GIP and GLP-1 from enteroendocrine cells in response to oral glucose intake, while intravenous glucose does not (Figure 2). The contribution of incretin hormones to insulin secretory responses after oral glucose administration depends on the dose used and can vary between 25% and 75%. These hormones increase within minutes of nutrient intake and act on the islets of Langerhans to increase insulin secretion and decrease glucagon secretion when plasma glucose concentration is greater than approximately 6 mmol/L [7,9].
Incretin effect in people with Type 2 Diabetes
In people with type 2 diabetes, the incretin effect is greatly reduced or absent compared to healthy subjects (Figure 3). The question then arises: Does the decrease in the incretin effect precede and potentially promote the development of diabetes? Or is it a consequence of the diabetic state? Numerous studies have proposed that this defect occurs after the diagnosis of diabetes. Indeed, in patients with chronic pancreatitis, the reduced incretin effect is seen only in those who also develop diabetes and not in those who do not. Studies with intensive insulin therapy suggest that reduction of hyperglycemia would improve but not normalize the insulinotropic activity of GIP and GLP-1 in type 2 diabetes. In addition, it is believed that the inability of the endocrine pancreas to respond to GIP could contribute to the progression of diabetes. The loss of this physiological mechanism would further deteriorate glycemic control, giving rise to a vicious circle by worsening glucotoxicity that can induce a reduction in β-cell mass, the functional capacity and expression of GIP receptors, and the incretin effect [10-12].
Given the decrease in the incretin effect in type 2 diabetes, pharmacological therapies based on incretinomimetics have been developed. On the one hand, DDP-4 inhibitors that act by increasing the levels of active incretin hormones by inhibiting the enzyme that physiologically inactivates them. On the other hand, GLP-1 analogs act by stimulating GLP-1 receptors. Both are recommended as second-line treatment for type 2 diabetes [11].
Since meal-stimulated GIP concentrations were similar in people with and without type 2 diabetes while GLP-1 concentrations were reduced in type 2 diabetes, treatment strategies were targeted at GLP-1. Recent clinical studies have identified potential benefits of GIP in combination with GLP-1 [13].
Currently, the American Diabetes Association recommends the use of GLP-1R agonists in patients with type 2 diabetes at risk of atherosclerotic cardiovascular disease, heart failure, or established kidney disease [24].
Regarding obesity, randomized studies have shown that greater initial weight loss achieved with lifestyle changes associated with pharmacological strategies improves long-term weight maintenance. The relationship between energy intake and expenditure is modulated not only by environmental and behavioral factors, but also genetic and hypothalamic-regulated neuroendocrine feedback mechanisms. It integrates peripheral hormonal signals from the gastrointestinal tract (ghrelin, cholecystokinin, peptide YY, pancreatic polypeptide, GLP-1), pancreas (insulin), and adipose tissue (leptin). There are molecules that stimulate appetite (central orexigenic effect) such as neuropeptide Y (NPY) and agouti-related peptide (AgRP) and others that suppress appetite (central anorexigenic effect), for example alpha-melanocyte-stimulating hormone (α- MSH), a peptide derived from pro-opiomelanocortin (POMC) and the cocaine and amphetamine regulated transcript (CART). In animal studies, GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in NPY- and AgRP-expressing neurons through ϒ-aminobutyric acid (GABA)-dependent signaling. These findings indicate that GLP-1 receptors on POMC/CART-expressing arcuate nucleus neurons likely mediate weight loss induced by exogenous GLP-1 analogs [14].
DPP-4 enzyme inhibitors
DPP-4 inhibitors are orally available low molecular weight drugs that rapidly and specifically inhibit DPP-4 activity. The most commonly used are sitagliptin, vidagliptin, and saxagliptin. These have few side effects, improving active GLP-1 and GIP levels 2-3 times after a meal, and also appear to have similar glycemic efficacy: a modest (0.5-0.8%) reduction in HbA1c. The risk of hypoglycemia with DPP-4 inhibitors is low given their GLP-1 mediated glucose-dependent mechanism of action [8].
GLP-1 analogs
The GLP-1 analogs present in our country are liraglutide, semaglutide and dulaglutide. In routine clinical practice, we could classify them as those administered daily, such as liraglutide, or administered weekly, such as semaglutide and dulaglutide [8]. The most commonly used GLP-1 analogs are listed below:
Liraglutide. It shares 97% homology with native GLP-1, but unlike
the latter has a half-life of 13 hours. It was first approved for the treatment of type 2 diabetes in Europe in 2009 and it was only in December 2014 that the 3.0 mg dose of liraglutide was first signed up for the treatment of obesity in the United States of America [14,15].
Regarding its effect on weight loss, Mancino et al. in a 20-week trial it compared liraglutide versus orlistat versus placebo. Orlistat is a potent, specific, and long-acting inhibitor of gastrointestinal lipases approved for the treatment of obesity. Patients (n = 564, BMI 30-40 kg/m2) were assigned to the following doses of liraglutide: 1.2; 1.8; 2.4 and 3.0 mg (n = 90-95) or placebo (n = 98) administered once daily subcutaneously or orlistat (n = 95) 120 mg 3 times daily orally. As shown in Figure 4, liraglutide induced significantly greater weight loss than placebo (P = 0.003 for liraglutide 1.2 mg and P < 0 xss=removed xss=removed xss=removed xss=removed>
On the other hand, human studies have shown that endogenous GLP-1 has positive effects on blood pressure (BP) and on endothelial function in patients with type 2 diabetes. These have been confirmed with GLP-1 receptor agonists (GLP-1A). They not only improve glycemic control, lipid profile, BP, and weight, but also cardiac function and ischemia, resulting in the prevention or delay of the atherosclerotic process. Although Buen et al. maintain that this atheroprotective role would be through the modulation of macrophage activity, the exact mechanisms are not yet fully elucidated [16,17].
In 2016, one of the most relevant CVOT studies (in English: Cardiovascular Outcome Trial) on the subject was published: LEADER, in which 32 countries participated. It was multicenter and randomized. It included 9340 patients with DM2 and high cardiovascular risk. Liraglutide 1.8 mg/day (or the maximum tolerated dose) was compared with placebo. Patients were followed for 3.8 years and demonstrated a 13% reduction in the risk of major adverse cardiac events (MACE), reduction in HbA1c, body weight, and hypoglycemia. There were no significant differences in hospitalization for heart failure or the development of pancreatitis. It showed a reduction in the risk of mortality from cardiovascular causes by 22% and was well tolerated, although it was associated with mild gastrointestinal disorders [18]. The most common side effects were nausea and diarrhea. These appeared in the first weeks of treatment and were related to the dose (Figure 5). To avoid them, it is recommended to start with 0.6 mg/day and increase by 0.6 mg daily each week until reaching a daily dose of 1.8 mg in people with type 2 diabetes or 3 mg/day for obesity treatment [18].
Semaglutide
It shares 94% homology with native GLP-1. present a life longer median than liraglutide. Modifications of its chemical structure compared to endogenous GLP-1 include two amino acid substitutions at position 8 (alanine for alpha-amino isobutyric acid) and 34 (lysine for arginine), and also acylation of lysine at position 26 with a "linker" composed of a glutamic acid moiety and a C-18 fatty diacid side chain. Substitution at position 8 makes it resistant to degradation by DPP-4, and the linker promotes its binding to albumin, extending its half-life to about 1 week. In 2016, a trial was published to assess long-term cardiovascular outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN-6). 3,297 type 2 diabetic patients from 20 countries were given semaglutide once weekly (0.5 mg or 1.0 mg) versus placebo for 104 weeks [20,23]. In relation to body weight, at week 104 and compared with the placebo group, those who received 0.5 mg semaglutide presented a decrease of 2.9 kg and those who received 1 mg the decrease was 4.3 kg (Figure 6). Regarding cardiovascular outcomes, in SUSTAIN-6, semaglutide demonstrated a 26% reduction in MACE, 39% in the development of stroke, and 26% in the occurrence of cardiovascular events at 2 years, when added to standard treatment. In addition, a 36% reduction in the risk of progression or new onset of kidney disease was observed [20]. Finally, gastrointestinal disorders were more frequent in the semaglutide group. Nausea, vomiting and diarrhea were the most observed [20].
Dulaglutide
It comprises two molecules of modified GLP-1 covalently linked to a immunoglobulin G (IgG) heavy chain molecule, has a half-life of 5 days and is administered subcutaneously in weekly doses of 0.75 mg or 1.5 mg. It is currently used in several countries of the European Union and the United States [16, 21].
In 2019, the REWIND study designed to assess whether the addition of dulaglutide to the diabetes medication regimen in adults with T2DM safely reduces the incidence of cardiovascular outcomes compared to placebo was published. This trial lasted 3 years, 24 countries and 9901 patients with DM2 participated. In it, one group received a weekly injection of 1.5 mg of dulaglutide and the other group a placebo. The findings show that dulaglutide reduces cardiovascular events and this could be due to the reduction in HbA1c levels, LDL cholesterol, BP and weight. Evidence also suggests that these drugs could enhance endothelial cell responses to ischemia, attenuate the progression of atherosclerosis, vascular inflammation, and vasoconstriction [21].
REWIND demonstrated a significant reduction in MACE-3 (nonfatal acute myocardial infarction, nonfatal stroke, and cardiovascular mortality) of 12%. In REWIND only 32% of the individuals studied had established cardiovascular disease [21]. In this way, dulaglutide would be the first GLP-1 analogue to demonstrate cardiovascular benefit in a population without already established cardiovascular disease (unlike the LEADER and SUSTAIN-6 studies). From there arises the possibility of using it for primary cardiovascular prevention in type 2 diabetes. Regarding the treatment of obesity, its use has not yet been approved for it.
There is a strong association between obesity and type 2 diabetes. Establishing healthy eating habits and physical activity substantially improve short-term health, but the long-term success rate is low given the complex pathophysiology involved and the difficulty in maintaining changes in lifestyle. From the discovery of incretins and their decrease or absence in diabetic patients, therapeutic strategies arise in this area. There is extensive scientific evidence on the benefit of the use of GLP-1 analogs, mainly liraglutide, semaglutide, dulaglutide and exenatide (the latter is currently not available in Argentina) for the treatment of obesity and diabetes. CVOT multicenter studies such as LEADER, SUSTAIN-6 and REWIND, confirmed that the benefits of long-term use of these drugs are mainly at the cardiovascular and renal levels. They reduce HbA1c levels, arterial hypertension and regulate dyslipidemia. They also decrease platelet aggregation and thrombosis while increasing myocardial contractility. On the other hand, they slow gastric emptying and appetite, increase insulin sensitivity, and decrease gluconeogenesis. The American Diabetes Association (ADA) recommends the use of these GLP-1R agonists in patients with DM2 and existing cardiovascular and renal failure. Liraglutide is approved in our country for use in type 2 diabetes and obesity. Semaglutide and Dulaglutide only for type 2 diabetes, although semaglutide has recently been approved in the United States for the treatment of obesity.
Finally, it is necessary to highlight the necessary role of the clinical analysis laboratory not only in the diagnosis of diabetes, but also in the dosage of biochemical markers that allow monitoring the evolution of patients under pharmacological therapy with incretin analogs.
GIP: glucose-dependent insulinotropic polypeptide
GLP-1: Glucagon-like peptide-1
DPP-4: Dipeptidyl peptidase enzyme – 4
GIP-R: Glucose-dependent insulinotropic polypeptide receptor
GLP-1R: Glucagon-like peptide receptor-1
cAMP: Cyclic Adenosine Monophosphate PKA: Protein Kinase A
BMI: Body Mass Index BP: Blood Pressure
LDL: Low density lipoprotein
HbA1c: Hemoglobina glicosilada A1C
GLP-1A: Análogo del péptido similar al glucagón-1
DM2: DiabetesMellitus tipo 2
IgG: Inmunoglobulina G
REWIND: Researching Cardiovascular Events with a Weekly Incretin in Diabetes
EXCEL: Effectsof Once-Weekly Exenatideon Cardiovascular Outcomes in Type 2 Diabetes
HDL: High density lipoprotein
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
